SYRE · Spyre Therapeutics, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on SYRE. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About SYRE · Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Live Quote
BUY (score +7) · 12-1 mom 382.3% · RSI 72.1 · above_both · -3.3% from high
Targets blend Wall Street consensus (15 analysts: low $78.00 / mean $100.47 / high $135.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Spyre Therapeutics is a clinical-stage biotech that has generated exceptional price appreciation (+370% YTD to ~$74) on positive Phase 2 UC data (SPY001 SKYLINE trial, April 2026) and concurrent $463M equity raise. The investigation trigger was met — 3+ Form 4s in 14 days — but ALL recent transactions are pre-arranged 10b5-1 SELLs or board option grants, not open-market purchases. Zero genuine insider buy signals exist among recent filings. The company has six Phase 2 readouts expected across Q3-Q4 2026 (SKYLINE UC and SKYWAY rheumatic basket), with SPY072 TL1A expansion into RA/PsA/axSpA. However, the stock is near all-time highs after massive dilution (~10M new shares in April offering) and insider selling at elevated levels. The combination of zero open-market insider buys + recent material dilution at these prices + weak options flow with no IV premium → this is not an asymmetric long setup.